Perceptic, a London-based startup founded by former Palantir executives, has successfully secured $12 million in a seed funding round. The investment was led by Accel with participation from Air Street Capital and Elder Gull to advance its AI operating system for drug development. The company aims to unify the entire pharmaceutical lifecycle, from initial research and development to final clinical decision-making.
Addressing Fragmentation in Pharmaceutical R&D
The pharmaceutical industry has long struggled with a fragmented development process, where critical data is isolated within disconnected systems. This siloed approach creates significant inefficiencies, slows decision-making, and contributes to costly late-stage failures. While AI adoption is growing, most solutions have focused on improving individual steps rather than addressing the entire workflow.
A Unified AI Operating System
Perceptic offers a solution by providing a single, shared intelligence layer that acts as connective tissue across the drug lifecycle. Its platform is designed to unify asset scouting, scientific evaluation, and clinical data foundations on one system. This integrated approach ensures that insights from one stage are carried forward, creating a compounding effect on knowledge.
The system utilizes specialized AI agents to harmonize public, proprietary, and external data sources while automating complex due diligence tasks. As an infrastructure-agnostic platform, it allows clients to integrate their existing models and data seamlessly. Crucially, the technology ensures every claim can be traced to its source, eliminating the risk of AI-generated inaccuracies.
Accelerating Innovation and Investor Confidence
Early users of Perceptic's platform, including the biotechnology firm CSL, report significant improvements in efficiency and data capture. The technology can compress the time required for scientific due diligence from weeks to mere hours. This acceleration of go-no-go decisions demonstrates the platform's immediate impact on speeding up portfolio triage and evaluation.
Investor confidence is high, with Accel partner Sonali De Rycker highlighting the platform's unique ability to "follow the drug" through its entire journey. This end-to-end vision distinguishes Perceptic from competitors focused on siloed departmental tools. The investment reflects a belief that unified platforms will reshape how drug projects advance from concept to clinic.
Future Plans and Market Position
With the new capital, Perceptic plans to scale its engineering team in London and expand its presence in the United States to grow its customer base. The company, now around 20 employees, is focused on moving beyond its initial product-market fit to broader deployment. This strategic expansion will be crucial for capturing a larger share of the life sciences market.
Perceptic's $12 million funding round marks a significant step toward resolving long-standing fragmentation in the pharmaceutical industry. By providing a unified AI operating system, the company is poised to shorten development timelines and reduce the costs of innovation. This positions Perceptic as a pivotal force in transforming how new therapies are discovered, developed, and delivered to patients.